Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

2.

Herpesvirus saimiri infection of rhesus macaques: a model for acute rhadinovirus-induced t-cell transformation and oncogenesis.

Rosenwirth B, Kondova I, Niphuis H, Greenwood EJ, Schmidt F, Verschoor EJ, Wittmann S, Heeney JL, Bogers WM, Fickenscher H, Koopman G.

J Med Virol. 2011 Nov;83(11):1938-50. doi: 10.1002/jmv.22197.

PMID:
21915869
3.

Debio-025 inhibits HIV-1 by interfering with an early event in the replication cycle.

Daelemans D, Dumont JM, Rosenwirth B, De Clercq E, Pannecouque C.

Antiviral Res. 2010 Feb;85(2):418-21. doi: 10.1016/j.antiviral.2009.10.009. Epub 2009 Oct 24.

PMID:
19857522
4.

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, de Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B.

Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17. doi: 10.1128/AAC.01324-07. Epub 2008 Jan 22.

5.

Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination.

Aspinall R, Pido-Lopez J, Imami N, Henson SM, Ngom PT, Morre M, Niphuis H, Remarque E, Rosenwirth B, Heeney JL.

Rejuvenation Res. 2007 Mar;10(1):5-17.

PMID:
17378748
6.

Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.

Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V.

J Med Primatol. 2007 Feb;36(1):2-9.

PMID:
17359459
7.

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J.

Hepatology. 2006 Apr;43(4):761-70.

PMID:
16557546
8.

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.

Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, Jones MJ, Stoddart CA, Scalfaro P, Dumont JM, Besseghir K, Rosenwirth B, Gallay PA.

J Biol Chem. 2005 Dec 2;280(48):40293-300. Epub 2005 Sep 30.

9.

Readily acquired secondary infections of human and simian immunodeficiency viruses following single intravenous exposure in non-human primates.

ten Haaft P, Verschoor EJ, Verstrepen B, Niphuis H, Dubbes R, Koornstra W, Bogers W, Rosenwirth B, Heeney JL.

J Gen Virol. 2004 Dec;85(Pt 12):3735-45.

PMID:
15557247
10.

Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)).

Holterman L, Dubbes R, Mullins J, Learn G, Niphuis H, Koornstra W, Koopman G, Kuhn EM, Wade-Evans A, Rosenwirth B, Haaijman J, Heeney J.

J Virol. 2001 Oct;75(19):9328-38.

11.

Independence of herpesvirus-induced T cell lymphoma from viral cyclin D homologue.

Ensser A, Glykofrydes D, Niphuis H, Kuhn EM, Rosenwirth B, Heeney JL, Niedobitek G, Müller-Fleckenstein I, Fleckenstein B.

J Exp Med. 2001 Mar 5;193(5):637-42.

12.

Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques.

Rosenwirth B, Kuhn EM, Heeney JL, Hurpin C, Tartaglia J, Bonnet MC, Moingeon P, Erdile L.

Vaccine. 2001 Feb 8;19(13-14):1661-70.

PMID:
11166889
13.

Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicity.

Glykofrydes D, Niphuis H, Kuhn EM, Rosenwirth B, Heeney JL, Bruder J, Niedobitek G, Müller-Fleckenstein I, Fleckenstein B, Ensser A.

J Virol. 2000 Dec;74(24):11919-27.

14.

A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens.

Heeney JL, Koopman G, Rosenwirth B, Bogers W, van Dijk J, Nieuwenhuis I, Niphuis H, ten Haaft P, Hanke T, Rhodes G, Berglund P, Burny A, Bex F, Sutter G, Liljeström P.

J Med Primatol. 2000 Aug;29(3-4):268-73.

PMID:
11085589
15.

Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.

Rosenwirth B, ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, Bischofberger N, Heeney JL, Uberla K.

J Virol. 2000 Feb;74(4):1704-11.

16.

Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus.

Verschoor EJ, Davis D, van Gils M, Koopman G, Mooij P, Oostermeijer H, Haaft PT, Verstrepen B, Rosenwirth B, Morein B, Barnett SW, Heeney JL.

J Med Primatol. 1999 Aug-Oct;28(4-5):224-32.

PMID:
10593489
17.

An anti-HIV strategy combining chemotherapy and therapeutic vaccination.

Rosenwirth B, Bogers WM, Nieuwenhuis IG, Haaft PT, Niphuis H, Kuhn EM, Bischofberger N, Erfle V, Sutter G, Berglund P, Liljestrom P, Uberla K, Heeney JL.

J Med Primatol. 1999 Aug-Oct;28(4-5):195-205.

PMID:
10593486
18.

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

Heeney J, Akerblom L, Barnett S, Bogers W, Davis D, Fuller D, Koopman G, Lehner T, Mooij P, Morein B, de Giuli Morghen C, Rosenwirth B, Verschoor E, Wagner R, Wolf H.

Immunol Lett. 1999 Mar;66(1-3):189-95.

PMID:
10203054
19.
20.

The interleukin-17 gene of herpesvirus saimiri.

Knappe A, Hiller C, Niphuis H, Fossiez F, Thurau M, Wittmann S, Kuhn EM, Lebecque S, Banchereau J, Rosenwirth B, Fleckenstein B, Heeney J, Fickenscher H.

J Virol. 1998 Jul;72(7):5797-801.

21.

T-cell lymphoma caused by herpesvirus saimiri C488 independently of ie14/vsag, a viral gene with superantigen homology.

Knappe A, Thurau M, Niphuis H, Hiller C, Wittmann S, Kuhn EM, Rosenwirth B, Fleckenstein B, Heeney J, Fickenscher H.

J Virol. 1998 Apr;72(4):3469-71.

22.

Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta.

Bogers WM, Dubbes R, ten Haaft P, Niphuis H, Cheng-Mayer C, Stahl-Hennig C, Hunsmann G, Kuwata T, Hayami M, Jones S, Ranjbar S, Almond N, Stott J, Rosenwirth B, Heeney JL.

Virology. 1997 Sep 15;236(1):110-7.

24.

Plasmodium vivax: in vitro antiparasitic effect of cyclosporins.

Kocken CH, van der Wel A, Rosenwirth B, Thomas AW.

Exp Parasitol. 1996 Dec;84(3):439-43.

PMID:
8948333
25.

The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus.

Borvak J, Chou CS, Van Dyke G, Rosenwirth B, Vitetta ES, Ramilo O.

J Infect Dis. 1996 Oct;174(4):850-3.

PMID:
8843228
26.

Kinetics and isotype profile of rheumatoid factor production during viral infection: organ distribution of antibody secreting cells.

Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavölgyi E.

Scand J Immunol. 1996 Sep;44(3):273-84.

PMID:
8795722
27.

Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase.

Ettmayer P, Billich A, Hecht P, Rosenwirth B, Gstach H.

J Med Chem. 1996 Aug 16;39(17):3291-9.

PMID:
8765512
28.

Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.

Oren DA, Zhang A, Nesvadba H, Rosenwirth B, Arnold E.

J Mol Biol. 1996 May 31;259(1):120-34.

PMID:
8648640
29.

Interactions of HIV-1 proteins with human T-cell cyclophilin A.

Hammerschmid F, Billich A, Wasserbauer E, Rosenwirth B.

Ann N Y Acad Sci. 1996 May 15;782:456-61. No abstract available.

PMID:
8659916
30.
31.

Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.

Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Rosenwirth B, Seifert J, McCune JM.

Antimicrob Agents Chemother. 1996 Mar;40(3):750-4.

32.

IgG isotype-specific auto-antibodies bind preferentially to cross-linked membrane Ig.

Fazekas G, Pálfi G, Wolff-Winiski B, Rosenwirth B, Dukor P, Gergely J, Rajnavölgyi E.

Int Immunol. 1995 Jul;7(7):1125-34.

PMID:
8527410
33.

SDZ PRI 053, an orally bioavailable human immunodeficiency virus type 1 proteinase inhibitor containing the 2-aminobenzylstatine moiety.

Billich A, Fricker G, Müller I, Donatsch P, Ettmayer P, Gstach H, Lehr P, Peichl P, Scholz D, Rosenwirth B.

Antimicrob Agents Chemother. 1995 Jul;39(7):1406-13.

35.

SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.

Rosenwirth B, Oren DA, Arnold E, Kis ZL, Eggers HJ.

Antiviral Res. 1995 Jan;26(1):65-82.

PMID:
7741522
36.

In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent.

Rosenwirth B, Kis ZL, Eggers HJ.

Antiviral Res. 1995 Jan;26(1):55-64.

PMID:
7741521
37.

IgG isotype distribution of local and systemic immune responses induced by influenza virus infection.

Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavölgyi E.

Eur J Immunol. 1994 Dec;24(12):3063-7.

PMID:
7805734
38.

HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization.

Billich A, Charpiot B, Fricker G, Gstach H, Lehr P, Peichl P, Scholz D, Rosenwirth B.

Antiviral Res. 1994 Dec;25(3-4):215-33.

PMID:
7710270
39.

Functional association of cyclophilin A with HIV-1 virions.

Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Göttlinger HG.

Nature. 1994 Nov 24;372(6504):363-5.

PMID:
7969495
40.

Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity.

Scholz D, Billich A, Charpiot B, Ettmayer P, Lehr P, Rosenwirth B, Schreiner E, Gstach H.

J Med Chem. 1994 Sep 16;37(19):3079-89.

PMID:
7932531
41.

In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages.

Perno CF, Aquaro S, Rosenwirth B, Balestra E, Peichl P, Billich A, Villani N, Caliò R.

J Leukoc Biol. 1994 Sep;56(3):381-6.

PMID:
8083612
42.

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog.

Rosenwirth B, Billich A, Datema R, Donatsch P, Hammerschmid F, Harrison R, Hiestand P, Jaksche H, Mayer P, Peichl P, et al.

Antimicrob Agents Chemother. 1994 Aug;38(8):1763-72.

43.

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, et al.

Antimicrob Agents Chemother. 1994 Apr;38(4):668-74.

44.

Measurement of HIV-1 reverse transcriptase by a nonradioactive assay system.

Hammerschmid F, Maier E, Rosenwirth B.

Ann N Y Acad Sci. 1992 Nov 30;672:252-6.

PMID:
1282311
45.
46.

Biologically active protease 3C of human rhinovirus 1A is expressed from a cloned cDNA segment in Escherichia coli.

Aschauer B, Werner G, McCray J, Rosenwirth B, Bachmayer H.

Virology. 1991 Oct;184(2):587-94.

PMID:
1653490
48.

Mechanism of action of 5-(2-chloroethyl)-2'-deoxyuridine, a selective inhibitor of herpes simplex virus replication.

De Clercq E, Bernaerts R, Merta A, Rosenwirth B.

Mol Pharmacol. 1990 May;37(5):658-64.

PMID:
2160059
49.

Synthesis and antiviral activity of thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazinyl ketones.

Easmon J, Heinisch G, Holzer W, Rosenwirth B.

Arzneimittelforschung. 1989 Oct;39(10):1196-201.

PMID:
2610710
50.

Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.

Griengl H, Hayden W, Penn G, De Clercq E, Rosenwirth B.

J Med Chem. 1988 Sep;31(9):1831-9.

PMID:
2842506

Supplemental Content

Loading ...
Support Center